Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data

Stratification of patients with severe asthma by blood eosinophil counts predicts responders to anti-interleukin (IL)-5 (mepolizumab and reslizumab) and anti-IL-5 receptor α (benralizumab) therapies. This stud...

Source: Allergy, Asthma and Clinical Immunology - April 24, 2018 Category: Allergy & Immunology Authors: Don Husereau, Jason Goodfield, Richard Leigh, Richard Borrelli, Michel Cloutier and Alain Gendron Tags: Research Source Type: research